Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease [Phase 2]

View source ↗

Summary

Phase 2 trial assessing efficacy and safety of apremilast (CC-10004) for Behçet disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Behçet Disease
• Behçet Syndrome

Drugs mentioned

• Apremilast (apremilast)

Snippet

Sponsor: Amgen | Conditions: Behcet Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2014-08-27